Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic potential of statins in thyroid proliferative disease

  • Viewpoint
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bifulco M et al. (1999) Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. Biochimie 81: 287–290

    Google Scholar 

  2. Vitale M et al. (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependant mechanism. Endocrinology 140: 698–704

    Google Scholar 

  3. Laezza C et al. (2006) HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. J Mol Med 84: 967–973

    Google Scholar 

  4. Cappelli C et al. (2008) Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. Clin Endocrinol (Oxf) 68: 16–21

    Google Scholar 

  5. Wang CY et al. (2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88: 3021–3026

    Google Scholar 

  6. Zhong WB et al. (2005) Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12: 615–629

    Google Scholar 

  7. Laezza C et al. (1998) V-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Proc Natl Acad Sci USA 95: 13646–13651

    Google Scholar 

  8. Bifulco M (2005) Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci 77: 1740–1749

    Google Scholar 

  9. Libertini S et al. (2007) Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 148: 5186–5194

    Google Scholar 

  10. Friedman GD et al. (2007) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf [10.1002/pds.1507]

Download references

Acknowledgements

The author's work is supported by the Associazione Educazione e Ricerca Medica Salernitana (ERMES).

Author information

Author notes

  1. Department of Pharmaceutical Sciences, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano (Salerno), Italy maubiful@unisa.it

Authors and Affiliations

  1. M Bifulco is Full Professor of General Pathology in the Department of Pharmaceutical Sciences, University of Salerno, Italy.,

    Maurizio Bifulco

Authors
  1. Maurizio Bifulco
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bifulco, M. Therapeutic potential of statins in thyroid proliferative disease. Nat Rev Endocrinol 4, 242–243 (2008). https://doi.org/10.1038/ncpendmet0782

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0782

  • Springer Nature Limited

This article is cited by

Search

Navigation